No Updates for GSK’s Cell Therapy Assets; New GSK Expected to Launch in July 2022; GSK’s Q1 2022 Earnings Call Summary
On Wednesday, April 27, GSK held their Q1 2022 earnings call (press release / presentation) highlighting that their business separation is anticipated to occur in July 2022. Of note, GSK did not provide any updates on their cell therapy assets. Below, Celltelligence provides insights on how lete-cel’s (NY-ESO-1 TCR-T) potential approval timeline compares with Adaptimmune’s afami-cel (MAGE-A4 SPEAR-T), while discussing GSK’s business separation.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.